These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20733267)

  • 1. Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
    Okada K; Yagyu H; Kotani K; Miyamoto M; Osuga J; Nagasaka S; Ishibashi S
    Endocr J; 2010; 57(10):903-8. PubMed ID: 20733267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.
    Thongtang N; Lin J; Schaefer EJ; Lowe RS; Tomassini JE; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Dec; 225(2):388-96. PubMed ID: 23040830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
    Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
    Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.
    Jakulj L; Vissers MN; Groen AK; Hutten BA; Lutjohann D; Veltri EP; Kastelein JJ
    J Lipid Res; 2010 Apr; 51(4):755-62. PubMed ID: 19828909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens.
    Malina DM; Fonseca FA; Barbosa SA; Kasmas SH; Machado VA; França CN; Borges NC; Moreno RA; Izar MC
    J Clin Lipidol; 2015; 9(4):542-52. PubMed ID: 26228672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
    Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
    Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale.
    Inazawa T; Sakamoto K; Kohro T; Iijima R; Kitazawa T; Hirano T; Kawamura M; Tagami M; Tanaka A; Mori Y; Yamazaki T; Shiba T;
    Lipids Health Dis; 2013 Oct; 12():142. PubMed ID: 24094079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.